Description
National Program, coordinated by the Ministry of Health and financed via the National Health Insurance House, provides access to innovative lipid-lowering therapies for patients after an acute coronary syndrome, at high cardiovascular risk, with familial hypercholesterolemia, or with statin intolerance. It includes PCSK9 inhibitors – Alirocumab (Praluent) and Evolocumab (Repatha). Program has been integrated into a common IT platform, with frequent reporting of quality metrics and outcomes monitoring, to optimize outpatient management.Program launch date
2015-ongoingResponsible entity
Single National Health Social Insurance FundAvailable results and quality metrics
Approximately 8500 patients were given the therapy with PCSK9i in 2024, based on internal Insurance House data analysis (from an eligible population calculated at 237,532 patients).Limitations / comments
Extending the number, close to the calculated eligible population.